About: Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) հոդված (hy) artículu científicu (ast) wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2013 (uk) article scientifique publié en 2013 (fr) im März 2013 veröffentlichter wissenschaftlicher Artikel (de) 2013 മാര്‍ച്ച് 14 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം (ml)
publication date	wds:Q64012993-65479143-97EE-4D53-B062-FC87F8111AE5
publication date	2013-03-14 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64012993-8D53AB57-0041-42F1-9134-C490C34C40D4
language of work or name	English
exact match	wds:Q64012993-3B8EB010-D50B-458C-A67D-06BD596F6590
exact match	https://scigraph.springernature.com/pub.10.1038/clpt.2013.54
cites work	wds:Q64012993-03F315A3-381D-45CD-87E9-8B77917C16C2 wds:Q64012993-04EF4C5A-9526-463B-ADBC-1C77E0C5FFD8 wds:Q64012993-0B94D3B4-48E7-4C0F-9A90-669B5E7820FB wds:Q64012993-0E9FAFD7-B468-420F-AE04-148FB361E57C wds:Q64012993-0ED09183-9751-4676-862C-0EEB017EFC4D wds:Q64012993-0F272AA9-C96F-441B-8162-5C5BF581F90D wds:Q64012993-16A3FBCB-5168-46BE-9BF1-C6B152CA2AC8 wds:Q64012993-26EF7817-E47C-4963-9E62-92B128EC4092 wds:Q64012993-2A01F95D-1363-4957-90CB-74D2339E9F82 wds:Q64012993-2D8CF8FA-C8C2-4BAA-B3FF-B7D0833129D6 wds:Q64012993-2FD20A4A-8340-4671-8901-3161FB920665 wds:Q64012993-35AB69E8-0F1D-476C-A2C7-DE7092E1E936 wds:Q64012993-35FB8DD8-C842-42CF-B375-929A67CAF091 wds:Q64012993-3A7C960D-43B2-4E85-BA2D-413473DDCF97 wds:Q64012993-3B673B28-7999-4413-A6A8-AD663C51CA8A wds:Q64012993-3B952143-B2F0-4D00-A494-304F8D20CECB wds:Q64012993-3E099101-CF55-4489-82FA-8DCAE7E4AA10 wds:Q64012993-48EE3006-B3CF-411C-B267-3DA73A1F9081 wds:Q64012993-4D0D5C38-140F-455F-A125-0AC6D142DD61 wds:Q64012993-4D9BFE28-3075-43EA-9FFB-E5FF495BBE20 wds:Q64012993-5898010A-880C-409E-8542-C977500157F4 wds:Q64012993-59C17B96-D936-4F0B-BEBA-661E0E0518F4 wds:Q64012993-608F398F-E86F-4D6C-9A3A-D4229B2F3D18 wds:Q64012993-6B73A881-C2D8-4FA2-A92A-4EA369A4C7D3 wds:Q64012993-7B1DA4D1-C99D-4F2D-9DBF-F151316C9CD2 wds:Q64012993-7DE30C4C-74CE-488F-812F-2E3CD530423F wds:Q64012993-819F68A3-72D2-4F63-ACB4-0A456F6551F1 wds:Q64012993-82FE7474-9D35-4BB8-BD0D-0CDA47EB993E wds:Q64012993-8A0E5173-E385-432F-B9BE-409AB0D3EDEE wds:Q64012993-8C9896E0-B06A-4E29-8F1D-1B78B5FE57FC wds:Q64012993-925485A8-D21C-405B-8BF3-C9CF20932D15 wds:Q64012993-9F7659AC-B97A-4AF2-B7A2-17E873CA9515 wds:Q64012993-A0CBF8D2-10A3-4ECB-8548-6A2F860E3745 wds:Q64012993-A0F7820E-BCCA-485F-95A0-6F1176A78B66 wds:Q64012993-A4A316FA-65AE-4FC5-BB92-B9F3EE83DDEB wds:Q64012993-A8EDF7DE-D9BC-4E1F-82AE-3AD579F9E3D0 wds:Q64012993-AB6BCFAE-6108-4802-9FA4-54E5584898AD wds:Q64012993-AFF6F95D-9CD2-428A-B812-31D23C964CBD wds:Q64012993-B0298C8B-CA15-4DFE-B2BA-E8A1DB2CC2E0 wds:Q64012993-B0CA5C87-B8E2-412C-A4C6-5725034DDC58 wds:Q64012993-B2D48E70-3670-4E7B-B491-831705F7661B wds:Q64012993-B61A8FE6-F08B-4D10-9447-78E8F3E575E9 wds:Q64012993-B7B02FB5-5332-4E72-A57B-264978B68259 wds:Q64012993-C4E110C3-36CC-4E1D-9C80-5139F947CAB6 wds:Q64012993-CBB84AAB-54D6-423E-A5B2-0EB2451F4A96 wds:Q64012993-CC734EA5-28FC-4675-8879-A1BD1F797504 wds:Q64012993-D7017219-31A5-4D2A-A5EA-133A4B7AC92A wds:Q64012993-D8C61A43-2007-49C9-948C-877710C9F964 wds:Q64012993-E2B437F6-6316-47AC-A105-0354A0229B7D wds:Q64012993-EAD27358-7704-49C2-A252-24DAB52C52C5 wds:Q64012993-ED4E61D9-BCE7-4289-9CB9-E1CE5D029BBF wds:Q64012993-F5F77CE1-CA81-49D1-96F9-64568A63825D wds:Q64012993-F87C310B-AA2A-4989-925C-2478EC0F98B6
cites work	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Prevalence and genesis of endometriosis Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement Can animal models of disease reliably inform human studies? Learning versus confirming in clinical drug development Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor Model-based drug development Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software